| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers A > Headlines for aaiPharma Inc. > News item |
aaiPharma opens phase 1 clinic in North Carolina, hires clinical development heads
By Caroline Salls
Pittsburgh, Jan. 23 - aaiPharma Inc. has opened a new clinic in the Research Triangle Park area in Morrisville, N.C., that will increase the company's phase 1 clinical trial capacity in the United States to 144 beds, according to a company news release.
The clinic will be used to conduct bio-equivalence trials and is in addition to the company's 65-bed phase 1 unit in Germany.
"The expansion of our phase 1 capacity and the strengthening of our global clinical operations are important steps in our strategy to reposition the company as a strong, global drug development company," president and chief executive officer Ludo J. Reynders said in the release.
The company has also appointed George Perentesis and Brian O'Keeffe to lead and expand its clinical operations worldwide.
Perentesis will head aaiPharma's North American clinical operations, and O'Keeffe will head its European clinical operations.
Perentesis has more than 20 years of clinical development experience in the pharmaceutical and contract research industry, including positions at Schering Plough, Novo Nordisk and PRA International. Most recently, he was vice president of research and development at Sucampo Pharmaceuticals Inc., according to the release.
O'Keeffe has worked in research and development within the pharmaceutical and development services industry for more than 20 years. Most recently, he worked with the government contracting organization Abt Associates. Before this, he was president of Quintiles Asia Pacific and medical director for Bayer in the United Kingdom and in Singapore.
aaiPharma, a Wilmington, N.C., pharmaceutical company, filed for bankruptcy on May 31, 2005 in the U.S. Bankruptcy Court for the District of Delaware. Its Chapter 11 case number is 05-11341.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.